ClinicalTrials.gg
RecruitingNCT07291037TROPION-Lung17Updated Nov 10, 2026

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

A Phase 3 interventional study of Datopotamab deruxtecan (Dato-DXd) and Docetaxel in Non-small Cell Lung Cancer (NSCLC), sponsored by AstraZeneca. Recruiting at 206 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Updated Nov 10, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung — 7 open to participants now, 19 under way, 9 of them phase 3. datopotamab deruxtecan · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
10th of 21
400 · median 278
Started
2025
with 3 others
Phase 3
9 of 21
3 open now
Primary completion
2029-01
later than 12 of 18 live
Registered
20th of 21
by date
Lead sponsor
11 of 21
AstraZeneca

Among the 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung, this one is the 10th largest by planned enrollment, is one of 4 that started in 2025, is one of 9 in phase 3, reaches primary completion later than 12 of the 18 other live ones, and was the 20th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

7 of the 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About datopotamab deruxtecan

datopotamab deruxtecan: first FDA approval 2025 (DATROWAY), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable genomic alterations (AGA).

Read the detailed description

TROPION-Lung17 is a phase III, 2-arm, randomised, open-label, multicentre study, assessing the efficacy and safety of Dato-DXd compared with docetaxel in participants with previously treated trophoblast cell surface protein 2 (TROP2) normalised membrane ratio (NMR) positive advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA), and to assess the clinical performance of the investigational in vitro diagnostic (IVD) device.

03

Conditions studied

  • Non-small Cell Lung Cancer (NSCLC)

Keywords

  • TROPION-Lung17
  • Non-small cell lung cancer (NSCLC)
  • Advanced non-squamous NSCLC
  • Metastatic non-squamous NSCLC
  • Datopotamab deruxtecan (Dato-DXd; DS-1062a)
  • Docetaxel
  • Trophoblast cell surface protein 2 (TROP2)
  • Normalised membrane ratio (NMR)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- documented Stage IIIB, IIIC, or Stage IV non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) at the time of randomisation and meets the criteria for NSCLC:

  • Participants must have documented negative test results for EGFR (eg, exon 19 deletion or exon 21 L858R, exon 21 L861Q, exon 18 G719X, or exon 20 S768I mutation), ALK, and ROS1 genomic alterations.

Note: If test results for EGFR, ALK, and ROS1 are not available, participants are required to undergo prospective testing performed centrally for these genomic alterations in a Sponsor-designated central laboratory.

  • Has no known tumour genomic alterations in NTRK, BRAF V600, RET, MET exon 14 skipping, KRAS G12C, or . Additionally, participants must not have known tumour genomic alteration of any other actionable driver oncogenes for which there are locally approved targeted therapies.

Note: Participants whose tumours harbour BRAF (exception V600) or KRAS (exception G12C) mutations are eligible for the study.

  • Prospectively assessed TROP2 NMR positive based on results from an appropriately validated TROP2 RxDx device in a Sponsor- designated, regulatory compliant central laboratory.

    • Documentation of radiographic disease progression while on or after receiving the most recent treatment regimen for advanced or NSCLC.
    • Participants must have received platinum based chemotherapy (PBC) in combination with anti-programmed death-protein 1 ()/anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody (mAb) as the only prior line of therapy or received PBC and anti-PD-1/anti-PD-L1 monoclonal antibody (in either order) sequentially as the only 2 prior lines of therapy.
    • Provision of acceptable formalin fixed and paraffin embedded (FFPE) tumour sample for assessment of TROP2.
    • At least one lesion not previously irradiated that qualifies as a , Version 1.1 (RECIST 1.1) target lesion (TL) at baseline and can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) and is suitable for accurate repeated measurements.
    • (ECOG) Performance Status (PS) of 0 or 1.
    • Adequate bone marrow reserve and organ function within 7 days before randomisation.

Exclusion criteria

Exclusion Criteria:

  • Squamous, mixed NSCLC, or small cell lung cancer (SCLC) histology.
  • NSCLC disease that is eligible for definitive local therapy alone.
  • History of another primary other than NSCLC, except for malignancy treated with curative intent with no known active disease within 3 years before randomisation and of low potential risk for recurrence.
  • Spinal cord compression or , unless asymptomatic, stable, and not requiring treatment with or anticonvulsants for at least 7 days prior to randomisation.
  • corneal disease.
  • Has active or uncontrolled or C virus infection.
  • Known (HIV) infection that is not well controlled.
  • Uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals.
  • History of ILD/pneumonitis, including radiation pneumonitis (apart from radiation pneumonitis that did not require steroids), or drug-induced ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening. Examples of suspected ILD/pneumonitis by imaging include the presence of lung parenchymal fibrosis, such as combined pulmonary fibrosis and emphysema (CPFE), and any radiographic features consistent with interstitial lung abnormalities, including but not limited to, extensive ground glass opacities, reticular opacities, traction bronchiectasis, and honeycombing.
  • Has severe pulmonary function compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (eg, pulmonary emboli within 3 months of the study enrolment, severe asthma, severe , restrictive lung disease, symptomatic pleural effusion, etc).
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Arm A: Datopotamab deruxtecan (Dato-DXd) monotherapy

    Participants in the Dato-DXd monotherapy group will receive Dato-DXd as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

    Drug: Datopotamab deruxtecan (Dato-DXd)

  • Active comparator
    Arm B: Docetaxel monotherapy

    Participants in the docetaxel monotherapy group will receive docetaxel as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

    Drug: Docetaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    PFS is defined as the time from randomization until radiological progression per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR), or death due to any cause.

    Time frame: Approximately 2.5 years

  2. Overall survival (OS)

    OS is defined as the time from randomization until the date of death due to any cause.

    Time frame: Approximately 3.5 years

Secondary outcomes

  1. Objective response rate (ORR)

    ORR is defined as the proportion of participants who have a confirmed complete response (CR) or confirmed partial response (PR), as determined by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).

    Time frame: Approximately 2.5 years

  2. Duration of response (DoR)

    DoR is defined as the time from the date of first documented response until the date of documented progression per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1), as assessed by Blinded Independent Central Review (BICR) or death due to any cause.

    Time frame: Approximately 2.5 years

  3. Time to second progression or death (PFS2)

    PFS2 is defined as the time from randomization until the earliest of the progression event (following the initial progression event), after first subsequent therapy, or death. The date of the second progression will be recorded by the Investigator in the electronic Case Report Form (eCRF) and defined according to local standard clinical practice based on radiological or clinical progression.

    Time frame: Approximately 2.5 years

  4. Participant-reported lung cancer symptoms of non-small cell lung cancer (NSCLC)

    Time to deterioration (TTD) in pulmonary symptoms (dyspnoea, cough, and chest pain). TTD is defined as time from randomization to the date of first deterioration. Deterioration is defined as change from baseline that reaches an meaningful change threshold (MCT).

    Time frame: Approximately 2.5 years

  5. Participant-reported physical functioning

    Time to deterioration (TTD) in physical functioning. TTD is defined as time from randomization to the date of first deterioration. Deterioration is defined as change from baseline that reaches a meaningful change threshold (MCT).

    Time frame: Approximately 2.5 years

  6. Participant-reported global health status (GHS)/quality of life (QoL)

    Time to deterioration (TTD) in GHS/QoL. TTD is defined as time from the date of randomisation to the date of first deterioration. Deterioration is defined as change from baseline that reaches a meaningful change threshold (MCT)

    Time frame: Approximately 2.5 years

  7. Diagnostic development and biomarker assay concordance analysis

    Evaluate the relationship between TROP2 NMR status at a defined cutoff and efficacy endpoints, as determined by the diagnostic device.

    Time frame: Approximately 2.5 years

07

Study locations

182 of 206 sites recruiting
  • Research Site
    Chandler, Arizona 85224, United States
    Recruiting
  • Research Site
    Gilbert, Arizona 85234, United States
    Recruiting
  • Research Site
    Goodyear, Arizona 85338, United States
    Recruiting
  • Research Site
    Duarte, California 91010, United States
    Recruiting
  • Research Site
    Irvine, California 92618, United States
    Recruiting
  • Research Site
    La Jolla, California 92093, United States
    Recruiting
  • Research Site
    Loma Linda, California 92350, United States
    Recruiting
  • Research Site
    Los Angeles, California 90095, United States
    Recruiting
  • Research Site
    San Diego, California 92123, United States
    Recruiting
  • Research Site
    Grand Junction, Colorado 81501, United States
    Recruiting
  • Research Site
    Wheat Ridge, Colorado 80033, United States
    Recruiting
  • Research Site
    Newark, Delaware 19713, United States
    Recruiting
  • Research Site
    Washington D.C., District of Columbia 20037, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Fort Myers, Florida 33901, United States
    Recruiting
  • Research Site
    Jacksonville, Florida 32224, United States
    Recruiting
  • Research Site
    St. Petersburg, Florida 33709, United States
    Recruiting
  • Research Site
    Tampa, Florida 33612, United States
    Recruiting
  • Research Site
    West Palm Beach, Florida 33401, United States
    Recruiting
  • Research Site
    Marietta, Georgia 30060, United States
    Recruiting
  • Research Site
    Newnan, Georgia 30265, United States
    Recruiting
  • Research Site
    Chicago, Illinois 60612, United States
    Recruiting
  • Research Site
    Chicago, Illinois 60637, United States
    Recruiting
  • Research Site
    Hinsdale, Illinois 60521, United States
    Recruiting
  • Research Site
    Niles, Illinois 60714, United States
    Recruiting
  • Research Site
    Zion, Illinois 60099, United States
    Recruiting
  • Research Site
    Louisville, Kentucky 40207, United States
    Recruiting
  • Research Site
    South Portland, Maine 04106, United States
    Recruiting
  • Research Site
    Baltimore, Maryland 21201, United States
    Recruiting
  • Research Site
    Brandywine, Maryland 20613, United States
    Recruiting
  • Research Site
    Boston, Massachusetts 02215, United States
    Recruiting
  • Research Site
    Detroit, Michigan 48202, United States
    Recruiting
  • Research Site
    Rochester, Minnesota 55905, United States
    Recruiting
  • Research Site
    Bridgeton, Missouri 63044, United States
    Recruiting
  • Research Site
    Columbia, Missouri 65212, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Lincoln, Nebraska 68516, United States
    Recruiting
  • Research Site
    Albuquerque, New Mexico 87109, United States
    Recruiting
  • Research Site
    East Syracuse, New York 13057, United States
    Recruiting
  • Research Site
    Portland, Oregon 97239, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Hershey, Pennsylvania 17033, United States
    Recruiting
  • Research Site
    Lancaster, Pennsylvania 17601, United States
    Recruiting
  • Research Site
    Greenville, South Carolina 29607, United States
    Recruiting
  • Research Site
    Memphis, Tennessee 38120, United States
    Recruiting
  • Research Site
    Austin, Texas 78745, United States
    Recruiting
  • Research Site
    Denton, Texas 76201, United States
    Recruiting
  • Research Site
    Plano, Texas 75075, United States
    Recruiting
  • Research Site
    Charlottesville, Virginia 22908, United States
    Recruiting
  • Research Site
    Fairfax, Virginia 22031, United States
    Recruiting
  • Research Site
    Williamsburg, Virginia 23188, United States
    Recruiting
  • Research Site
    Tacoma, Washington 98405, United States
    Recruiting
  • Research Site
    Morgantown, West Virginia 26506, United States
    Recruiting
  • Research Site
    Eau Claire, Wisconsin 54703, United States
    Recruiting
  • Research Site
    Gosford, 2250, Australia
    Recruiting
  • Research Site
    Kogarah, 2217, Australia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    South Brisbane, 4101, Australia
    Recruiting
  • Research Site
    St Albans, 3021, Australia
    Recruiting
  • Research Site
    Wollongong, 2500, Australia
    Recruiting
  • Research Site
    Graz, 8036, Austria
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Linz, 4021, Austria
    Not yet recruiting
  • Research Site
    Rankweil, 6830, Austria
    Recruiting
  • Research Site
    Vienna, 1140, Austria
    Recruiting
  • Research Site
    Vienna, 1210, Austria
    Recruiting
  • Research Site
    Hasselt, 3500, Belgium
    Recruiting
  • Research Site
    La Louvière, 7100, Belgium
    Recruiting
  • Research Site
    Libramont-Chevigny, 6800, Belgium
    Recruiting
  • Research Site
    Sint-Niklaas, 9100, Belgium
    Recruiting
  • Research Site
    Yvoir, 5530, Belgium
    Recruiting
  • Research Site
    Porto Alegre, 90610-000, Brazil
    Recruiting
  • Research Site
    Porto Alegre, 91350-200, Brazil
    Recruiting
  • Research Site
    Salvador, 40170-110, Brazil
    Recruiting
  • Research Site
    São Paulo, 01246-000, Brazil
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    São Paulo, 01327-001, Brazil
    Recruiting
  • Research Site
    São Paulo, 05652-900, Brazil
    Recruiting
  • Research Site
    Vancouver, British Columbia VSZ 4E6, Canada
    Recruiting
  • Research Site
    Moncton, New Brunswick E1C 6Z8, Canada
    Recruiting
  • Research Site
    Halifax, Nova Scotia B3H 2Y9, Canada
    Recruiting
  • Research Site
    Brampton, Ontario L6R 3J7, Canada
    Recruiting
  • Research Site
    Hamilton, Ontario L8V 1C3, Canada
    Recruiting
  • Research Site
    Toronto, Ontario M5G 1X6, Canada
    Recruiting
  • Research Site
    Beijing, 100034, China
    Recruiting
  • Research Site
    Beijing, 100142, China
    Recruiting
  • Research Site
    Beijing, 101149, China
    Recruiting
  • Research Site
    Changchun, 130000, China
    Recruiting
  • Research Site
    Changsha, 410013, China
    Recruiting
  • Research Site
    Chengdu, 610041, China
    Recruiting
  • Research Site
    Chengdu, 610072, China
    Recruiting
  • Research Site
    Chongqing, 400030, China
    Recruiting
  • Research Site
    Fuzhou, 350011, China
    Recruiting
  • Research Site
    Guangzhou, 510080, China
    Recruiting
  • Research Site
    Hangzhou, 310022, China
    Recruiting
  • Research Site
    Harbin, 150081, China
    Recruiting
  • Research Site
    Hefei, 230610, China
    Recruiting
  • Research Site
    Jiamusi, 154007, China
    Recruiting
  • Research Site
    Jinan, 250117, China
    Recruiting
  • Research Site
    Nanchang, 330006, China
    Recruiting
  • Research Site
    Nanjing, 2100008, China
    Recruiting
  • Research Site
    Shanghai, 200030, China
    Recruiting
  • Research Site
    Shanghai, 200032, China
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Shanghai, 200433, China
    Recruiting
  • Research Site
    Shantou, 515041, China
    Recruiting
  • Research Site
    Shenyang, 110004, China
    Recruiting

Showing the first 100 of 206 sites across 21 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca (AZ) group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the European Federation of Pharmaceutical Industries and Associations (EFPIA)/Pharmaceutical Research and Manufacturers of America (PhRMA) Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jan 2029, 38 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 38 months is close to that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2025
First posted
Dec 18, 2025
StartActual
Oct 31, 2025
Primary completionEst.
Jan 29, 2029
CompletionEst.
Jan 29, 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
18 sites changed recruiting status (13 now recruiting, 4 now withdrawn, …)
Show 18 sites
  • Research Site · Hinsdale, United StatesNot yet recruiting→Recruiting
  • Research Site · Kogarah, AustraliaRecruiting→Withdrawn
  • Research Site · Graz, AustriaNot yet recruiting→Withdrawn
  • Research Site · Porto Alegre, BrazilSuspended→Recruiting
  • Research Site · São Paulo, BrazilSuspended→Recruiting
  • Research Site · Budapest, HungaryNot yet recruiting→Recruiting
  • Research Site · Győr, HungaryNot yet recruiting→Recruiting
  • Research Site · Gyula, HungaryNot yet recruiting→Withdrawn
  • Research Site · Szolnok, HungaryNot yet recruiting→Withdrawn
  • Research Site · Milan, ItalyNot yet recruiting→Recruiting
  • Research Site · Monza, ItalyNot yet recruiting→Recruiting
  • Research Site · A Coruña, SpainNot yet recruiting→Recruiting
  • Research Site · Barcelona, SpainNot yet recruiting→Recruiting
  • Research Site · Zaragoza, SpainNot yet recruiting→Recruiting
  • Research Site · London, United KingdomNot yet recruiting→Recruiting
  • Research Site · Kecskemét, HungaryNot yet recruiting→Suspended
  • Research Site · Rozzano, ItalyNot yet recruiting→Recruiting
  • Research Site · Seville, SpainNot yet recruiting→Recruiting
across 2 updates, Oct 13, 2026 – Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    4 sites changed recruiting status (3 now recruiting, 1 now suspended)
    Show 4 sites
    • Research Site · Budapest, HungaryNot yet recruiting→Recruiting
    • Research Site · Kecskemét, HungaryNot yet recruiting→Suspended
    • Research Site · Rozzano, ItalyNot yet recruiting→Recruiting
    • Research Site · Seville, SpainNot yet recruiting→Recruiting
    + 1 other change: verification date
  2. Oct 13, 2026
    16 sites changed recruiting status (12 now recruiting, 4 now withdrawn)
    Show 16 sites
    • Research Site · Hinsdale, United StatesNot yet recruiting→Recruiting
    • Research Site · Kogarah, AustraliaRecruiting→Withdrawn
    • Research Site · Graz, AustriaNot yet recruiting→Withdrawn
    • Research Site · Porto Alegre, BrazilSuspended→Recruiting
    • Research Site · São Paulo, BrazilSuspended→Recruiting
    • Research Site · Budapest, HungaryNot yet recruiting→Recruiting
    • Research Site · Budapest, HungaryNot yet recruiting→Recruiting
    • Research Site · Győr, HungaryNot yet recruiting→Recruiting
    • Research Site · Gyula, HungaryNot yet recruiting→Withdrawn
    • Research Site · Szolnok, HungaryNot yet recruiting→Withdrawn
    • Research Site · Milan, ItalyNot yet recruiting→Recruiting
    • Research Site · Monza, ItalyNot yet recruiting→Recruiting
    • Research Site · A Coruña, SpainNot yet recruiting→Recruiting
    • Research Site · Barcelona, SpainNot yet recruiting→Recruiting
    • Research Site · Zaragoza, SpainNot yet recruiting→Recruiting
    • Research Site · London, United KingdomNot yet recruiting→Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07291037
Lead sponsor
AstraZeneca
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Dec 18, 2025
Start date
Oct 31, 2025
Primary completion
Jan 29, 2029 (estimated)
Completion
Jan 29, 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Datopotamab deruxtecan

Start the discussion